Tetra Bio-Pharma Inc. Strengthens Senior Management Team

ORLEANS, Ontario, June 5, 2018 (GLOBE NEWSWIRE) - Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has strengthened its management team with the promotion of V.P. Financing and Business Development Robert (Bob) Bechard to Executive Vice President, Corporate Development and Licensing, and the hiring of Ofer Yifrach-Stav as Vice President Pharmaceutical Compliance and Quality.

In his new expanded role, Bob will lead Tetra Bio-Pharma's business development and be actively involved in fundraising and executing the Company's M&A strategy, while overseeing Investor Relations.

Bob has more than 25 years' experience in financing, including venture capital and corporate banking along with business development. He was a Senior Member of a Venture Capital fund that delivered top quartile returns investing in North American Biotech companies. During his venture days, he served on the Boards of more than 30 biotech companies and oversaw the negotiation of numerous strategic alliances with major pharmaceutical companies. Additionally, he managed numerous exits via the public market or an outright sale to large pharmaceutical companies on behalf of the venture capital funds. Bob brings sound operational experience from his time as Chief Business Officer for an R&D Management company and VP of Corporate Development for a drug delivery company. As a consultant, he assisted numerous biotech companies in the areas of fundraising, business development, corporate development and strategy.

"We are thrilled to have Bob as an integral member of Tetra Bio-Pharma's Senior Executive team. His vast experience and extensive international network will help drive the execution of our corporate strategy," said Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.

"I am excited to be able to play a more active role in helping Tetra Bio-Pharma realize its vision to make pharmaceutical grade cannabinoid-based products accessible to patients around the world," said Bob Bechard, EVP, Corporate Development and Licensing.

The new Vice President Pharmaceutical Compliance and Quality, Ofer Yifrach-Stav has extensive experience in pharmaceutical and medical device industries where he worked with major medical device, pharmaceutical and cosmetic companies in North America, Europe and Asia. During this time, he successfully lead the preparation of companies for Quality Audits by Health Canada, FDA, EU and Israeli Ministry of Health. Over the years he developed expertise in production process validations and other areas of quality assurance.

“Ofer Yifrach-Stav will play a key role in accelerating our pre-commercial activities in preparation of the marketing applications of PPP001 and PPP002. These activities include production scale-up activities and process validations required to ensure the completeness of the Quality file required for the marketing applications leading to the DIN,” added Guy Chamberland.

The corporation will be restructured to optimize operations by commercial markets. Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization. Tetra Veterinary Health was created for the commercialization of cannabinoid-based products for the pet product market. To take advantage of the post-legalization market, Tetra Natural Health was established to develop and sell cannabinoid-based OTC (self-care) products.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its vision, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition;

regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

More information at: www.tetrabiopharma.com

For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
bob@tetrabiopharma.com
(514) 817-2514

For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784

For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990 M: 1 514 232 1556